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Qualitative Protocol Development Tool 
 
The research protocol forms an essential part of a research project. It is a full description of the 
research study and will act as a ‘manual’ for members of the research team to ensure adherence to 
the methods outlined. As the study gets underway, it can then be used to monitor the study’s progress 
and evaluate its outcomes.  
The protocol should go into as much detail about the research project as possible, to enable the 
review bodies to fully understand your study. 
 
The use of this collated consensus guidance and template is not mandatory. The guidance and 
template are published as standards to encourage and enable responsible research.  
The document will:  
 Support researchers developing protocols where the sponsor does not already use a template  
 Support sponsors wishing to develop template protocols in line with national guidance  
 Support sponsors to review their existing protocol template to ensure that it is in line with 
national guidance.  
 
A protocol which contains all the elements that review bodies consider is less likely to be delayed 
during the review process because there will be less likelihood that the review body will require 
clarification from the applicant. 
 
We would appreciate self-declaration of how you’ve used this template so we are able to measure its 
uptake.  
Please indicate the compatibility of this template with any existing templates you already use by 
stating one of the following on the front of each submitted protocol: 
 This protocol has regard for the HRA guidance and order of content; OR 
 This protocol has regard for the HRA guidance; OR 
 This protocol does not have regard to the HRA guidance and order of content 
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STUDY SUMMARY 
 
Study Title Impact of systematic user testing of written guidance on the 
rate of moderate to severe errors made by hospital nurses 
during in situ simulation of the preparation and administration 
of an intravenous medicine: phase 1 – user testing 
Short title Effects of user testing injectable medicines guidance – phase 
1 
Study Design Iterative user testing interviews 
Study Participants Qualified nurses or midwives registered with the Nursing and 
Midwifery Council, who are accredited to prepare and 
administer intravenous medicines in an organisation providing 
NHS care and who have done this during at least 50% of 
working shifts during the past six months (or since 
authorisation if this was granted more recently). 
Planned Size of Sample (if applicable) 30 
Follow up duration (if applicable) N/A 
Planned Study Period March to December 2018 
Research Question/Aim(s) 
 
Research question (whole study): Is it possible to reduce the 
incidence of medication errors by improving the content, 
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providing technical information to health professionals? 
Objectives for the entire study are: 
1. To identify and resolve problems in a typical NHS 
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2. To compare the rates of preparation and administration 
errors associated with use of the original and user 
tested IMG monograph. 
3. To determine whether systematic user testing of the 
IMG is a cost-effective approach to improving patient 
safety. 
4. To advise the IMG Advisory Board on generic lessons 
learned during user testing which could be introduced 
to the entire guide during the next revision cycle. 
Only objectives 1 and 4 will be addressed during phase 1 of 
the study (this protocol). 
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the final results of the study to a lay audience. 
 
Individuals 
 
Dr Matthew Jones, NIHR Transitional Research Fellow, University of Bath will act as Chief 
Investigator. He will lead and carry out all aspects of the design, conduct, data analysis and 
interpretation, manuscript writing and dissemination of results associated with this study. 
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providing expert advice and mentoring in relation to all aspects of the design, conduct, data analysis 
and interpretation, manuscript writing and dissemination of results associated with this study. 
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STUDY PROTOCOL 
 
1 BACKGROUND 
 
There is little previous research investigating tools for preparing and testing technical information 
about medicines aimed at health professionals: only one study has been identified, which applied 
systematic user testing to improve the presentation of the Summary of Product Characteristics for two 
medicines[1]. Thus no systematic review in this area is possible. 
 
A considerable number of studies have been carried out in the related fields of patient medicines 
information and clinical guideline production. In these areas, systematic user testing has been shown to 
improve understanding and decrease reading time[1-4]. Recently published guidance on the 
implementation of clinical guidelines recommends user testing[5] and it is required in the development of 
patient information leaflets for licensed medicines[4]. User testing is therefore the current “gold standard” 
method for improving patient information and the presentation of information to clinical guideline 
committees. 
 
The major advantage of user testing is that it is based on potential users reading the document to 
locate key information and correctly use it to recommend appropriate actions and the reasons for 
them[4]. Problems and potential solutions are therefore identified. Iterative rounds of interviews with 
potential users are followed by document revision, until all problems are resolved[1,4,6]. Each interview 
involves direct questions to determine whether the interviewee can locate and use key points of 
information, followed by a semi-structured interview to explore opinions of more general issues (e.g. 
structure of the document, language used). This ensures that participants only give feedback once 
they have experience of using a document to locate information. 
 
During phase 1 (outlined in this protocol), this study will investigate the application of user testing to 
the NHS Injectable Medicines Guide (IMG). Standard user testing methodology will be applied to 
revise the IMG monograph for a high-risk medicine. The “users” during this process will be hospital 
and community nurses who regularly prepare and administer intravenous medicines. In phase 2 (not 
part of this protocol), the study will then investigate the outcomes achieved as a result of user testing, 
by measuring the effect of this process on the occurrence of medication errors in a randomised in situ 
simulation experiment carried out with hospital nurses on duty in their usual clinical environment. 
 
2 RATIONALE  
 
Medication errors are a serious and persistent problem in all healthcare systems. The number of 
reported errors has increased year-on-year, to more than 100,000 in England and Wales[7]. A review 
of reports between 2005 and 2010 found that 17% of errors resulted in patient harm, including 822 
cases of death or severe harm[7]. The incidence of errors is higher for injectable medicines, with 
systematic reviews suggesting an error rate of 35-50%[8,9]. In November 2016, an alert was issued 
highlighting 2200 reports since 2013 of incidents with just one intravenous medicine (phenytoin), 
resulting in four deaths, five cases of severe harm and 121 cases of moderate harm[10]. 
 
 Effects of user testing injectable medicines guidance – phase 1 sSH  
 
2 
 
In 2007, the National Patient Safety Agency required healthcare providers to provide protocols for the 
administration of injectable medicines[11], such as the NHS Injectable Medicines Guide (IMG). This is 
used by nurses in more than 125 hospitals to guide the administration of individual doses and is 
accessed more than 1.5 million times per year[12,13]. Such guidance must be written carefully, as 
difficulty finding relevant, unambiguous information in technical documents has been linked to serious 
medication errors[14-16]. Systematic reviews of factors contributing to patient safety incidents therefore 
include contradictory, incomprehensible or poor quality information[17,18]. It is therefore concerning that 
the IMG has been described as too detailed and confusing to likely users[13,19]. This suggests that 
improvements to the presentation of the information in the IMG might result in fewer errors. Such 
concerns are shared by the IMG advisory board (Susan Keeling, IMG Project Manager, personal 
communication, 28/10/2016). 
 
The IMG is therefore the ideal case study to use to investigate the wider question of whether 
improved written documents providing technical information to health professionals can reduce the 
incidence of medication errors. 
 
As has already been discussed, systematic user testing is the gold standard approach for improving 
the quality of written documents. However, the effect of user testing medicines information on the 
behaviour of readers has not been previously investigated, as the previous studies outlined above 
have measured outcomes such as understanding and reading time[1-4]. This study will therefore add to 
the understanding of the outcomes achieved by user testing, by measuring the effect of this process 
on the occurrence of medication errors. 
 
3 THEORETICAL FRAMEWORK 
 
Two theoretical frameworks underlie this study. The first is Reason’s Generic Error Modelling System 
(Figure 1), which was developed to categorise the psychological causes of human error in a variety of 
settings (including healthcare)[20]: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: diagrammatic representation of Reason’s Generic Error Modelling System. Reproduced from 
reference[21]. 
 
 Effects of user testing injectable medicines guidance – phase 1 sSH  
 
3 
 
Knowledge and rule-based medication errors are common[22] and can be avoided by ensuring healthcare 
professionals are well informed about the medicines in use[23]. This explains why contradictory, 
incomprehensible or poor quality information is a recognised cause of medication errors[17,18] and 
therefore provides the theoretical basis for improving patient safety by improving the quality of the 
Injectable Medicines Guide. 
 
The second theoretical framework was developed by Rosenbaum to describe the user experience of a 
designed artefact, specifically documents used in the development of evidence-based clinical 
guidelines[24]. It is based on previous frameworks and the findings of Rosenbaum’s own work with 
documents used by the Cochrane Collaboration. The framework describes eight facets of a user’s 
experience of a document and how the relative importance of these facets changes as the user become 
more familiar with it. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Rosenbaum’s user experience framework[24] 
 
The various facets of user experience in this framework can be briefly defined as[24]: 
 
 Accessibility: are there physical barriers to users gaining access to the document? 
 Findability: can users locate what they are looking for? 
 Usefulness: does the document have practical value for users? 
 Usability: how easy and satisfying is the document to use? 
 Understandability: this covers two types of comprehension. Firstly, do users understand what type 
of document they are looking at? And secondly, do users correct understand the content of the 
document in the way that the author intended? 
 Credibility: is the document trustworthy? 
 Desirability: is the document something the user wants or has a positive emotional response to? 
 Affiliation: do users believe the document is intended to be used by “someone like me”? 
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The three modes of use over time can be briefly defined as: 
 Recognition: the process by which users locate a document and categorise it uses 
 Exploration: the process by which users understand how to they should use a document 
 Reliance: users no longer ask “how to use” a document, but rely upon it as they attend to the 
primary task at hand. Disruptions may occur in this mode, which move the user back into the 
exploration mode. 
 
Rosenbaum’s user experience framework will therefore be used to provide a theoretical underpinning to 
the design and analysis of the user testing interviews, to ensure that all aspects of a user’s experience 
are explored. 
 
4 RESEARCH QUESTION/AIM(S) 
 
Research question (whole study): Is it possible to reduce the incidence of medication errors by 
improving the content, wording, structure and formatting of written documents providing technical 
information to health professionals? 
 
This question will be investigated using the NHS Injectable Medicines Guide as a case study from one 
of the highest risk routes of medicines administration. 
 
4.1 Objectives 
 
Objectives for the entire study are: 
1. To identify and resolve problems in typical NHS Injectable Medicines Guide (IMG) monographs 
using systematic user testing. 
2. To compare the rates of preparation and administration errors associated with use of the original 
and user tested IMG monographs. 
3. To determine whether systematic user testing of the IMG is a cost-effective approach to 
improving patient safety. 
4. To advise the IMG Advisory Board on generic lessons learned during user testing which could 
be introduced to the entire guide during the next revision cycle. 
 
Only objectives 1 and 4 will be addressed during phase 1 of the study (this protocol). 
 
1.2 Outcome 
 
By applying user testing to the IMG during phase 1, revised monographs will be produced. If this 
results in fewer errors during phase 2, it would be the first demonstration that user testing of technical 
information about medicines can address one of the known causes of errors. This would show that 
user testing can improve the safety of the IMG and the approach could be introduced to the entire 
guide. It would also suggest that the safety of the numerous other examples of technical information 
about medicines aimed at health professionals could be improved by user testing. 
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5 STUDY DESIGN and METHODS of DATA COLLECTION AND DATA ANALYIS 
 
On the advice of the Study Advisory Group, the IMG monographs for intravenous voriconazole and 
aminophylline will be the subject of this study. Voriconazole is an appropriate case study because it is 
widely used and nationally recognised as a high risk injectable medicine[25]. Finally, the preparation 
and administration of a these medicines includes all the major steps commonly required for 
intravenous medicines: reconstitution, dilution, short injection, short and continuous infusions. 
 
To prevent participants using prior knowledge of vancomycin, before user testing the monograph will 
be “anonymised” by changing: 
 Any mention of “voriconazole” to “bathicillin” 
 Any mention of “aminophylline” to “unimycin” 
 
Standard user testing methodology will be employed, involving iterative rounds of semi-structured 
interviews with potential users followed by document revision[1,4,6]. 
 
An interview schedule will be prepared by the Chief Investigator based on previously published user 
testing research, the Rosenbaum user experience framework (see Section 3) and the IMG monograph 
for voriconazole and aminophylline. Each interview will include direct questions to determine whether 
the interviewee can locate and correctly use specific points of information to recommend appropriate 
actions and the reasons for them. These questions will be followed by a semi-structured interview to 
explore opinions of more general issues (e.g. structure of the document, sub-headings, language 
used). The draft interview schedule will be circulated to the study Advisory Group for comment, before 
being tested in three pilot interviews. The interview schedule may evolve as data collection 
progresses, to ensure it adequately reflects issues raised during preceding interviews. 
 
Interviews will be carried out in person by the Chief Investigator in a private location convenient to the 
participant. They will be audio recorded using two encrypted digital recorders (one as a backup), and 
the interviewer will make field notes. As soon as practical, the recordings will be transferred to the 
University of Bath’s secure research data storage facility and deleted from the digital recorders. 
Subsequently, the interview recordings will be transcribed by experienced transcribers employed by 
the host university. The Chief Investigator will remove any information which could potentially be used 
to identify a research participant from the transcripts before subsequent analysis. 
 
The data collection techniques will be piloted with three participants before substantive data collection 
begins. Data from the pilot phase will only be included in the main study if there are no substantive 
changes to the interview schedule or interview technique following the pilot. 
 
The primary outcome of each round will be the proportion of participants able to find and correctly use 
each specific point of information. This will be scored by the Chief Investigator using a list of 
appropriate actions and explanations. However, the full transcript of each interview will also be subject 
to thematic analysis, following the six stages described by Braun and Clarke[26]. This is an approach 
which allows the identification of recurrent themes and the exploration of their meaning[4,26]. Nvivo 
software will be used during this process. 
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After each round of user testing and data analysis, the IMG monographs will be revised based on the 
participants’ responses and information design best practice[27-29]. The revised monograph will then be 
tested in subsequent rounds. 
 
The costs of the interviews, data analysis and monograph revision process will be recorded 
throughout this phase for use in a health economic analysis during a later phase of the study. These 
will principally be the Chief Investigator’s time to collect and analyse data, and revise the monograph, 
and the participants’ time reviewing draft monographs. 
 
All electronic data will be stored on the University of Bath’s secure research data storage facility. 
Original copies of paper data sources (e.g. field notes) will be stored in a locked cabinet at the 
University of Bath. The data will be accessible only to the research team (Chief Investigator and above 
named advisors), sponsor’s representatives and (in the case of recordings) the transcribers (University 
of Bath employees). Data will be shared with team members outside the University of Bath using the 
secure files.bath file sharing facility (www.bath.ac.uk/guides/access-and-share-your-work-online-
using-files-bath/). Data will be stored for a minimum of ten years, in accordance with the University of 
Bath Research Data Policy (www.bath.ac.uk/research/data/policy/). Suitable anonymised data may be 
made available via the University of Bath Research Data Archive (https://researchdata.bath.ac.uk/).  
 
6 STUDY SETTING 
 
Qualified nurses will be recruited via at least three NHS hospitals. However, recruited staff will be 
interviewed in their own time. The location of the interviews may be at the participating organisations, 
but may also be elsewhere, including privately hired venues and the University of Bath. This is to 
provide maximum flexibility to meet the needs of participants, as this research method only requires a 
safe, quiet and undisturbed location. 
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7 SAMPLE AND RECRUITMENT 
 
7.1  Eligibility Criteria 
 
7.1.1 Inclusion criteria  
 
 Qualified nurse or midwife registered with the Nursing and Midwifery Council 
 Authorised to prepare and administer intravenous medicines in an organisation which 
provides NHS care 
 Has prepared and administered intravenous medicines during at least half of working 
shifts during the past six months (or since authorisation if this was granted more 
recently) 
 
7.1.2 Exclusion criteria  
 
 Has participated in a previous round of user testing for this study 
 Does not consent to interview being audio-recorded 
 
7.2  Sampling 
 
7.2.1  Size of sample 
 
The pilot phase will involve three participants. This will be followed by three rounds of user testing, 
each interviewing ten new participants. 
 
This sample size is based on standard user testing methodology[1,4,6]. As this is a form of diagnostic 
testing – finding out where documents do not work, and remedying problems using expert information 
writing and design practice – large numbers of participants are not needed. Experience shows that 
most significant flaws in a document are identified by the first few participants[6]. Hence, a formal 
sample size calculation is not appropriate[6,30]. 
 
7.2.2  Sampling technique 
 
As is standard practice in systematic user testing, participants for each round will be purposefully 
selected to include a range of nursing experience[1,4,6], based on the following sampling matrix. This 
approach will ensure that user feedback is obtained from a diverse sample which represents the range 
of relevant nursing experience found within the NHS. This will ensure that the final user tested 
document is useful for a wide range of nurses: 
 
Number of years accredited to prepare and administer IV 
medicines 
Hospital 
1 
Hospital 
2 
Hospital 
3 
<5 years 2 nurses 2 nurse 1 nurse 
≥5 years 2 nurses 2 nurse 1 nurse 
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A cut off of five years of experience preparing and administering intravenous medicines was chosen 
because evidence suggests that the number of errors with which a nurse is involved decreases over 
the first four to six years of their nursing experience[31-34]. In particular, one study found that the risk of 
intravenous medicine administration errors decreased with each year of a nurse’s experience up to six 
years[31]. 
 
Each round of user testing will recruit new participants, to reduce bias related to previous participants 
having learned about the study monograph during their past interview. 
 
7.3  Recruitment 
 
7.3.1 Sample identification 
 
Each site will advertise the study to eligible staff via email, intranet sites, leaflets, posters and 
promotion via the nursing hierarchy. Participating sites will identify staff who potentially meeting the 
inclusion/exclusion criteria for targeting with the above advertising methods. Interested staff will be 
invited to contact the Chief Investigator if they meet believe they meet the inclusion/exclusion criteria 
and would like to participate. At this point, potential participants will be required to share identifiable 
personal information with the Chief Investigator, such as contact details, employer and details of 
nursing experience, to be used for eligibility screening. 
 
Participants’ reasonable travel expenses will be reimbursed at University of Bath rates 
(www.bath.ac.uk/finance-procurement/guidance/travel-expenses/mileage-rates/index.html). In 
addition, participants will be offered a £25 shopping voucher to acknowledge their time contribution. 
 
7.3.2 Consent 
 
Informed consent will be obtained from all participants and recorded in writing immediately prior to 
their interview. Interviews will not commence unless consent is obtained and documented. 
 
Participants will be provided with a paper or electronic copy of the approved participant information 
leaflet and consent form at least 24 hours in advance of their agreed interview appointment. 
Immediately prior to their interview, the Chief Investigator will discuss the contents of the participant 
information leaflet with the participant, highlighting the nature and objectives of the study and possible 
risks associated with participation. The participant will be given the opportunity to ask questions about 
any aspect of the study they do not fully understand. As participants in this study will be qualified, 
practising nurses, it is very likely that all potential participants will have capacity to consent. If the 
potential participant demonstrates the ability to retain and understand the information provided about 
the study, they will be deemed capable and asked to complete the consent form. 
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8 ETHICAL AND REGULATORY CONSIDERATIONS 
 
8.1 Assessment and management of risk 
 
This study presents a very low risk of harm to study participants. In non-interventional, interview-based 
studies such as this, the major risk is that of causing distress to participants through the discussion of 
upsetting situations. However, in this study, participants will be NHS staff (rather than patients) and 
interviews will focus on discussing the anonymised IMG monograph, rather than previous or 
anticipated real life events. The risk of causing distress to participants is consequently very small. 
Should a participant become distressed, the interview (and recording) will be paused to allow them to 
compose themselves. The interview will then only be continued once the participant is composed and 
if they wish to do so. 
 
The subject matter of the interviews also makes the disclosure of a participant’s intention to harm 
themselves or others extremely unlikely.  
 
8.2   Research Ethics Committee (REC) and other regulatory review & reports 
 
As participants in this study are NHS staff, review by an NHS Research Ethics Committee is not required. 
However, a favourable opinion will be sought from the University of Bath Research Ethics Approval 
Committee for Health for this protocol, informed consent forms and other relevant documents e.g. 
advertisements. 
 
Should any study amendments be required, the Chief Investigator will submit information to the 
University of Bath Research Ethics Approval Committee for Health in order for them to issue a 
favourable opinion for the amendment. 
 
Regulatory Review & Compliance 
 
Approval from the Health Research Authority will be obtained before the study commences. Before the 
study commences at any particular site, the Chief Investigator will ensure that the R&D department of 
that site has formally confirmed their capacity and capability to deliver the study. 
 
Should any study amendments be required, the Chief Investigator (in agreement with the sponsor) will 
submit information to the Health Research Authority in order for them to issue approval for the 
amendment. The Chief Investigator will then work with study sites’ R&D departments so they can put 
the necessary arrangements in place to implement the amendment and to confirm their support for the 
study as amended. 
 
Amendments  
 
Amendments will be submitted for approval and communicated as described above. The decision to 
make amendments will be made and implemented by the Chief Investigator, in line with advice from the 
Study Advisory Group and research advisors. The Sponsor will categorise amendments as substantial or 
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non-substantial in line with the current version of the University of Bath amendments process. 
Amendment history will be tracked through the use of version numbers of all documents and Appendix 3 
of this protocol. 
 
8.3  Peer review 
 
The proposal for this study was reviewed through the NIHR fellowship application process. This 
involved two rounds of review by a funding panel and peer review by three external experts. In 
addition, this protocol has been reviewed by Prof Theo Raynor (University of Leeds, one of the study 
research advisors and a leading researcher of the user testing technique) and Prof Margaret Watson 
(University of Bath). 
 
8.4  Patient & Public Involvement 
 
Two members of the public will be invited to become lay advisors for the study. The role of these advisors 
will be to assist with the dissemination of the research to a lay audience. They will be recruited via patient 
groups associated with the participating organisations. They will be invited to find out about the research 
from an early stage and observe data collection, to ensure more successful involvement and 
dissemination. 
 
In addition to the above, users were involved in the development of this study and its associated 
documents, specifically nurses and pharmacists, who will be the participants and end users of the 
research. 
 
A series of discussions were undertaken with a range of pharmacists and nurses involved with the 
design and use of the Injectable Medicines Guide, including members of the IMG advisory board, the 
UK Medicines Information network and the National Infusion and Vascular Access Society. 
 
These discussions covered the importance of the research question, the appropriateness of the 
proposed methods, the feasibility of carrying out the research and possible improvements. Feedback 
from these discussions confirmed that this is a timely project addressing a real need faced by 
practitioners. People emphasised that the IMG is currently written with little consideration for the 
needs of end users and gave examples from their own experience of the resultant problems. User 
testing was therefore viewed very favourably, from the perspective of potential participants and from 
the perspective of future IMG users. These conversations influenced this protocol by suggesting the 
inclusion of community nurses in the user testing. 
 
The Study Advisory Group (described above) will give practising nurses and pharmacists ongoing 
involvement in the management of this study and dissemination of the findings. 
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8.5 Protocol compliance 
 
The Chief Investigator will collect and analyse all data, so protocol deviations are less likely than in 
larger studies. However, accidental protocol deviations can occur at any time. 
 
A serious deviation from the protocol is defined as a one which is likely to effect to a significant 
degree: 
i. The safety or physical or mental integrity of the participants of the study, or 
ii. The scientific value of the study 
 
A protocol deviation may be identified through routine monitoring, internal audits or during the day to 
day running of the study. The Chief Investigator will make an assessment of the severity of the 
deviation. If it is classified as a ‘serious deviation’ according to the definition above the sponsor will be 
notified within 24 hours. 
 
Non-serious deviations (according to the definition above) will be documented e.g. in the field notes 
relating to the interview in questions. These deviations will be included and considered when the study 
report is produced, as they may have an impact on the analysis of data. However, non-serious 
deviations from the protocol which are found to frequently recur are not acceptable. They will be 
classified as a ‘serious deviation’ and immediate action will be taken to ensure they do not recur  
 
8.6 Data protection and participant confidentiality  
 
All investigators must comply with the requirements of the Data Protection Act 1998 with regards to the 
collection, storage, processing and disclosure of personal information and uphold the Act’s core 
principles. 
 
Personal information will be collected via consent forms, demographic data collection forms and audio 
recordings.  
 
Audio recordings will be made using encrypted, password protected digital recorders. As soon as 
possible after the interview, the recording will be transferred to a password protected folder in the 
University of Bath’s secure managed data storage facility, and deleted from the recorder. Recordings will 
subsequently be transcribed. Transcriptions will also be stored in a password protected folder in the 
University of Bath’s secure managed data storage facility and will be anonymised by replacing any 
potentially identifiable information with an unrelated sequence of characters. 
 
Data collection forms and consent forms will be returned to the University of Bath as soon as possible 
after completion, where they will be stored in a locked cabinet in a locked office. Demographic data will be 
transcribed to a file stored in a password protected folder in the University of Bath’s secure managed data 
storage facility. 
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Recordings, transcriptions and demographic data will be identified using only a unique participant 
number. The key linking these numbers to recognisable individuals will be stored in a separate secure 
location at the University of Bath and destroyed at the end of the research. 
 
Access to data will be limited to the Chief Investigator, research advisors, transcribers (recordings and 
transcriptions only, all transcribers will be University of Bath employees) and sponsor’s representatives. 
 
Data will be shared with team members outside the University of Bath using the secure files.bath file 
sharing facility (www.bath.ac.uk/guides/access-and-share-your-work-online-using-files-bath/). Data will 
be stored for ten years, in accordance with the University of Bath Research Data Policy 
(www.bath.ac.uk/research/data/policy/). Suitable anonymised data may be made available via the 
University of Bath Research Data Archive (https://researchdata.bath.ac.uk/). 
 
 
8.7 Indemnity 
 
The University of Bath has arranged Public Liability insurance to cover the legal liability of the 
University as Research Sponsor in the eventuality of harm to a research participant arising from 
management of the research by the University. 
 
The University of Bath holds Professional Indemnity insurance to cover the legal liability of the 
University as Research Sponsor and/or as the employer of staff engaged in the research, for harm to 
participants arising from the design of the research, where the research protocol was designed by the 
University. 
 
The University of Bath’s Public Liability and Professional Indemnity insurance policies provide an 
indemnity to our employees for their potential liability for harm to participants during the conduct of the 
research. 
 
8.8 Access to the final study dataset 
 
Access to the final dataset will be limited to the Chief Investigator, research advisors and sponsor’s 
representatives. In addition, suitable anonymised data may be made available via the University of Bath 
Research Data Archive (https://researchdata.bath.ac.uk/). 
 
9 DISSEMINIATION POLICY 
 
9.1  Dissemination policy 
 
Data arising from this study will be owned by the University of Bath. On completion of the study, data 
will be analysed and tabulated and a Final Study Report submitted to the NIHR. This report will be 
accessible via the NIHR. The Chief Investigator will have the right to publish any of the study data, 
subject to acknowledgement and approval of the submission by the NIHR. 
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Participants who express an interest in finding out about the results of the study will be sent a copy of 
the final study report. 
 
The study protocol, final study report and anonymised participant level dataset will be made publically 
available via the University of Bath Research Data Archive (https://researchdata.bath.ac.uk/) at the 
conclusion of the study. 
 
9.2  Authorship eligibility guidelines and any intended use of professional writers 
 
The author of the final study report will be the Chief Investigator. Authorship of academic publications 
arising from this study will be determined according to the International Committee of Medical Journal 
Editors criteria for defining the role of authors and contributors: 
 
 Substantial contributions to the conception or design of the work; or the acquisition, analysis, or 
interpretation of data for the work; AND 
 Drafting the work or revising it critically for important intellectual content; AND 
 Final approval of the version to be published; AND 
 Agreement to be accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and resolved. 
 
See: www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-
and-contributors.html 
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11.  APPENDICES 
 
11.1 Appendix 1 – Required documentation  
 CV of Chief Investigator 
 Participant information sheet 
 Consent form 
 Interview schedule 
 Interview data collection form 
 Recruitment email 
 Recruitment posters 
 
11.2  Appendix 2 – Schedule of Procedures 
 
Procedures Visits 
Interview 
Informed consent x 
User testing interview x 
 
 
13.3 Appendix 3 – Amendment History 
Amendment 
No. 
Protocol 
version no. 
Date issued Author(s) of 
changes 
Details of changes made 
1 1.1 2nd March 
2018 
Matthew 
Jones 
Test monograph changed from 
phenytoin to vancomycin, as suggested 
by Study Advisory Group. 
Amendments section revised to state 
that categorisation as substantial/non-
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substantial will be made by the 
sponsor, in line with University of Bath 
guidance. 
Minor changes to participant 
information sheet and ethnicity question 
removed from demographic data 
collection, as suggested by University 
of Bath Research Ethics Approval 
Committee for Health. 
2 1.2 4th 
September 
2019 
Matthew 
Jones 
Retrospective amendments to reflect 
how study was completed: 
 Test monographs changed to 
voriconazole and aminophylline 
following pilot study in April 2018, on 
advice of study advisory group. 
 No nurses were recruited via the two 
community care organisations 
approached, so recruitment section 
amended to reflect that nurses were 
only recruited from three hospitals. 
 
